“…While FGF21 was originally discovered as a liver-enriched FGF [8], it was subsequently shown to be a non-mitogenic metabolic regulator with therapeutic potential for obesity-related-metabolic dysfunction [9], [10], [11], [12], [13], [14], even in humans [15], [16]. More recently, the physiological context of FGF21 has been increasingly explored [17], [18], [19], with several studies from diverse laboratories now having shown that it is an endocrine signal of dietary PD in rodents [5], [20], [21], [22], [23], [24], [25] and in humans [5], [21], [26], [27]. While the downstream mechanisms by which FGF21 improves metabolic health with dietary PD are yet to be fully resolved, it is required for increased energy expenditure, at least in mouse models [5], [21], [22], and heightened energy expenditure is thought to be a promising strategy to combat obesity-related-metabolic disease [28].…”